By the Second

October 15, 2008

Lethality is difficult to comprehend.  A million people, ten million people, a hundred people dead–they are all more bodies than most of us can fathom.  Here are three desieses in terms of how often they kill a person.

Malaria: One person every 30 seconds.

AIDS: One person every 15 seconds.

TB: One person every 18 seconds.

It is far more lethal than Malaria and only a little behind the spectre of AIDS.  The problem should be self-evident.


Difficulties of Treatment

October 8, 2008

The New-England Journal of Medicine recommends that MDR-TB be treated with no less than for drugs and ideally seven.  These all have there own costs, schedules, and side effects.  There is a good deal of room to error and worsen the strains resistance.

In short it is impratcal to treat this disease and would take a toll on the finances and health (in the way of side-effects) of the patient.  This would compound the issues already at hand; it is a more difficult regimen to follow.  Prevention must be the answer to MDR-TB–and for that matter, TB in general.

A Question of Money?

October 8, 2008

I am certainly not the standard bearer for the pharmacutical industry; to be frank I feel they have minipulated the public’s ignorance of science to their own ends.  Having said that, I feel the information from Eli Lilly that I’m about to present is reliable enough.  After all, a drug gaining a resistance to one of Eli Lilly’s medicines would render the drug useless–in corperate terms, unprofitable.  To my surprise Eli-Lilly has taken steps against this illness in regions that pharmacutical companies usually ignore because of poverty.

One such place they have shown an unusual intrest is South Africa.  70% of the nation’s MDR-TB are also AIDS patients.  The company is providing businesses with information and cheap testing to help halt transmission (and further proliferate their anti-biotics when they can work, to be sure.)  Nonetheless many organazations have endorsed it as positive.  This all goes to show that there must be incentives if we hope to combat this disease.